Navigation Links
InspireMD Announces Participation in Two Investor Conferences in September
Date:8/29/2013

BOSTON, Aug. 29, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), today announced that the management team will present at the following investor conferences:

On Tuesday, September 10th, Alan Milinazzo, President and Chief Executive Officer of InspireMD, will present at the 15th Annual Rodman & Renshaw Global Investment Conference at the Millennium Broadway Hotel in New York City. The Company will present at 2:50 pm ET in Room 7.03, 7th Floor.

Investors unable to attend the Rodman conference may listen in to the webcast, which can be found on the Investors section of the Company's website at www.inspire-md.com/site_en/for-investors/. The webcast will be available for 90 days following the presentation.

On Thursday, September 12th, Mr. Milinazzo will present at the Stifel Annual Healthcare Conference at the Four Seasons Hotel in Boston, Massachusetts. The Company will present at 3:50 pm ET in the Winthrop room.

Investors attending the conferences who wish to meet with InspireMD management for one-on-one meetings are encouraged to contact their Rodman and Stifel representatives directly or InspireMD Investor Relations at InspireMD@kcsa.com.

A copy of the materials presented at both conferences will be available on the InspireMD investor relations website at www.InspireMD.com.

About Stenting and MGuard™ EPS

Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients, whose occlusion is different from that of an occlusion in a heart attack patie
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , BURLINGTON, Mass., Oct. 16 Palomar Medical ... researcher and developer of light-based systems for cosmetic ... with Johnson & Johnson Consumer Companies Inc ("JJCC"), ... test and commercialize home-use, light-based devices for (i) ...
... 16 Reportlinker.com announces that a new market ... Reportlinker Adds Pharma 101: An Overview ... , http://www.reportlinker.com/p0155107/Reportlinker-Adds-Pharma-101-An-Overview-of-the-Life-Sciences-Industry-(Analyst-Insight).html , Introduction , ... Without having the proper background, it can be ...
Cached Medicine Technology:Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 2Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 3Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 4Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 5Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight) 2
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/17/2014)... chronic inflammation in non-cancerous prostate tissue may have nearly ... those with no inflammation, according to results of a ... Kimmel Cancer Center. , The link between persistent inflammation ... high-grade prostate cancer those with a Gleason score ... the most aggressive and rapidly growing prostate cancers. , ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... several commonly-prescribed dementia drugs may be putting elderly Canadians ... , Cholinesterase inhibitors (Aricept, Exelon and Reminyl) are often ... because they increase the level of a chemical in ... drugs are known to provoke slower heart rates and ...
... Public Welfare Estelle B. Richman today responded to critics ... save taxpayers $146 million annually while preserving consumer benefits ... from the Smart Pharmacy initiative are real, not speculative," ... is facing a budget shortfall now and the savings ...
... pain condition common in people with migraines also ... headache, according to a study conducted by researchers ... for Neuroscience. , Approximately half of a group ... a condition that causes patients to have pain ...
... 27 UNICEF has appealed for an additional ... fighting in northwest Pakistan. Over half of the displaced are ... of supplies and funding. , , Humanitarian ... the number of people fleeing fighting that has taken place ...
... of Tennessee and Daiichi Sankyo ATLANTA, ... headquartered in Atlanta, has recently been awarded business ... BlueShield of Tennessee and Daiichi Sankyo, Inc.Studiocom,s healthcare ... these new clients meeting the challenges of the ...
... DIEGO, May 27 ResMed Inc. (NYSE: RMD ... upcoming conferences. David Pendarvis, SVP Organization Development and General Counsel ... the Four Seasons in Chicago on June 10, 2009 at ... CEO will present at the Jefferies Third Annual Healthcare Conference ...
Cached Medicine News:Health News:Dementia drugs may put some patients at risk, Queen's study shows 2Health News:Secretary of Public Welfare Corrects the Record on 'Smart Pharmacy' Initiative 2Health News:UNICEF Appeals for Funding to Urgently Assist Displaced Children and Women in Northwest Pakistan 2Health News:Studiocom Continues Growth with Healthcare Industry Wins 2Health News:Studiocom Continues Growth with Healthcare Industry Wins 3
... SuperAnchors are titanium alloy implants ... to bone. They are indicated ... required. The SuperAnchor uses four ... while maintaining small size. The ...
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... protection' -- providing complete protection from initial ... with side branches. , ,Proxis is ... not require the attachment or exchange of ... ,Proxis is compatible with all standard ...
... electrophysiology system on the market today, the ... patented "C inside a C" design offering ... ultimate in patient access and flexibility. Usable ... minimizes equipment footprint and can be parked ...
Medicine Products: